Brinker Capital Investments LLC Purchases 4,096 Shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)

Brinker Capital Investments LLC raised its position in shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR – Get Rating) by 13.2% in the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 35,143 shares of the biotechnology company’s stock after purchasing an additional 4,096 shares during the quarter. Brinker Capital Investments LLC’s holdings in Arrowhead Pharmaceuticals were worth $1,161,000 as of its most recent SEC filing.

A number of other large investors have also made changes to their positions in the company. BlackRock Inc. grew its stake in shares of Arrowhead Pharmaceuticals by 1.2% during the 1st quarter. BlackRock Inc. now owns 12,155,084 shares of the biotechnology company’s stock valued at $559,014,000 after purchasing an additional 147,021 shares during the period. Vanguard Group Inc. lifted its position in shares of Arrowhead Pharmaceuticals by 0.8% during the 1st quarter. Vanguard Group Inc. now owns 9,718,250 shares of the biotechnology company’s stock valued at $446,943,000 after buying an additional 78,107 shares in the last quarter. State Street Corp lifted its position in shares of Arrowhead Pharmaceuticals by 19.2% during the 2nd quarter. State Street Corp now owns 5,582,746 shares of the biotechnology company’s stock valued at $196,568,000 after buying an additional 900,791 shares in the last quarter. JPMorgan Chase & Co. lifted its position in shares of Arrowhead Pharmaceuticals by 2.4% during the 2nd quarter. JPMorgan Chase & Co. now owns 2,990,815 shares of the biotechnology company’s stock valued at $105,306,000 after buying an additional 69,862 shares in the last quarter. Finally, FMR LLC lifted its position in shares of Arrowhead Pharmaceuticals by 96.1% during the 2nd quarter. FMR LLC now owns 2,742,968 shares of the biotechnology company’s stock valued at $96,580,000 after buying an additional 1,344,444 shares in the last quarter. 65.46% of the stock is currently owned by institutional investors.

Arrowhead Pharmaceuticals Price Performance

Shares of ARWR opened at $33.76 on Friday. The stock has a market capitalization of $3.58 billion, a price-to-earnings ratio of -20.10 and a beta of 1.26. Arrowhead Pharmaceuticals, Inc. has a 1 year low of $26.81 and a 1 year high of $56.25. The business’s 50 day simple moving average is $33.90 and its 200-day simple moving average is $36.66.

Arrowhead Pharmaceuticals (NASDAQ:ARWR – Get Rating) last released its earnings results on Monday, November 28th. The biotechnology company reported ($0.81) earnings per share for the quarter, missing the consensus estimate of ($0.57) by ($0.24). The company had revenue of $31.58 million for the quarter, compared to the consensus estimate of $107.60 million. Arrowhead Pharmaceuticals had a negative net margin of 71.01% and a negative return on equity of 40.23%. On average, sell-side analysts expect that Arrowhead Pharmaceuticals, Inc. will post -0.59 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of research firms have recently weighed in on ARWR. Jefferies Financial Group lowered their price objective on Arrowhead Pharmaceuticals from $92.00 to $75.00 and set a “buy” rating on the stock in a research report on Tuesday, November 29th. Morgan Stanley lowered their price objective on Arrowhead Pharmaceuticals from $41.00 to $37.00 and set an “equal weight” rating on the stock in a research report on Tuesday, November 29th. B. Riley lowered their price target on Arrowhead Pharmaceuticals from $65.00 to $59.00 and set a “buy” rating on the stock in a report on Wednesday, November 30th. The Goldman Sachs Group reissued a “buy” rating and issued a $66.00 price target (up from $65.00) on shares of Arrowhead Pharmaceuticals in a report on Wednesday, November 30th. Finally, SVB Leerink lowered their price target on Arrowhead Pharmaceuticals from $33.00 to $31.00 and set a “market perform” rating on the stock in a report on Tuesday, November 29th. Three equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $59.22.

Insider Activity

In other Arrowhead Pharmaceuticals news, CFO Kenneth Allen Myszkowski sold 30,625 shares of the company’s stock in a transaction on Thursday, December 29th. The stock was sold at an average price of $40.00, for a total value of $1,225,000.00. Following the transaction, the chief financial officer now owns 336,704 shares of the company’s stock, valued at approximately $13,468,160. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other Arrowhead Pharmaceuticals news, CFO Kenneth Allen Myszkowski sold 30,625 shares of the company’s stock in a transaction on Thursday, December 29th. The stock was sold at an average price of $40.00, for a total value of $1,225,000.00. Following the completion of the sale, the chief financial officer now directly owns 336,704 shares in the company, valued at approximately $13,468,160. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director William D. Waddill sold 3,200 shares of the company’s stock in a transaction on Monday, January 9th. The stock was sold at an average price of $30.00, for a total value of $96,000.00. Following the completion of the sale, the director now owns 28,950 shares of the company’s stock, valued at $868,500. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 109,966 shares of company stock valued at $4,050,435. 3.20% of the stock is currently owned by insiders.

Arrowhead Pharmaceuticals Company Profile

(Get Rating)

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, which is in phase 2b and one phase 3 clinical trial to treat hypertriglyceridemia; ARO-ANG3 that is in phase 2b clinical trial for the treatment of dyslipidemia; ARO-HSD, which is completed phase 1/2 clinical trial to treat liver diseases; ARO-ENaC2, which is in pre-clinical stage for the treatment of dyslipidemia cystic fibrosis; ARO-C3 that is in phase 1/2a clinical trial to reduce production of complement component 3; ARO-DUX4, which is in pre-clinical stage for the treatment of facioscapulohumeral muscular dystrophy; ARO-XDH that is in phase 1 clinical trial to treat uncontrolled gout; ARO-COV, which is in pre-clinical stage for the treatment of COVID-19; ARO-RAGE, which is in phase 1/2a clinical trial to treat muco-obstructive or inflammatory pulmonary conditions; and ARO-MMP7 that is in phase 1/2a clinical trial for treatment of idiopathic pulmonary fibrosis.